Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset
Francesco Panza, Davide Seripa, Madia Lozupone, et al.
Expert Opinion on Biological Therapy (2017) Vol. 18, Iss. 1, pp. 25-35
Closed Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Current and Future Treatments in Alzheimer Disease: An Update
Konstantina G. Yiannopoulou, Sokratis G. Papageorgiou
Journal of Central Nervous System Disease (2020) Vol. 12, pp. 117957352090739-117957352090739
Open Access | Times Cited: 693
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review
Danko Jeremic, Lydia Jiménez‐Díaz, Juan D. Navarro‐López
Ageing Research Reviews (2021) Vol. 72, pp. 101496-101496
Open Access | Times Cited: 219
Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory
Pavan Srivastava, Prabhash Nath Tripathi, Piyoosh Sharma, et al.
European Journal of Medicinal Chemistry (2018) Vol. 163, pp. 116-135
Closed Access | Times Cited: 156
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Aseel Eid, Isha Mhatre‐Winters, Jason R. Richardson
Pharmacology & Therapeutics (2019) Vol. 199, pp. 173-187
Open Access | Times Cited: 119
An update on the novel and approved drugs for Alzheimer disease
Hassan A. Alhazmi, Mohammed Albratty
Saudi Pharmaceutical Journal (2022) Vol. 30, Iss. 12, pp. 1755-1764
Open Access | Times Cited: 68
Novel tacrine–benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer’s Disease
Gaia Fancellu, Karam Chand, Daniel Tomás, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2019) Vol. 35, Iss. 1, pp. 211-226
Open Access | Times Cited: 56
Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review
Vincenzo Solfrizzi, Pasquale Agosti, Madia Lozupone, et al.
Journal of Alzheimer s Disease (2018) Vol. 64, Iss. s1, pp. S229-S254
Closed Access | Times Cited: 53
Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
Niyanta N. Kumar, Michelle E. Pizzo, Geetika Nehra, et al.
Bioconjugate Chemistry (2018) Vol. 29, Iss. 12, pp. 3937-3966
Open Access | Times Cited: 50
Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer’s Disease
Kelly Ceyzériat, Thomas Zilli, P. Millet, et al.
Current Alzheimer Research (2020) Vol. 17, Iss. 2, pp. 112-125
Closed Access | Times Cited: 43
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Johannes Levin, Jonathan Vöglein, Yakeel T. Quiroz, et al.
Alzheimer s & Dementia (2022) Vol. 18, Iss. 12, pp. 2687-2698
Open Access | Times Cited: 26
Mitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022
Hongqi Wang, Xiaodong Yan, Yiming Zhang, et al.
Journal of Alzheimer s Disease Reports (2024) Vol. 8, Iss. 1, pp. 101-128
Open Access | Times Cited: 5
Peripheral Administration of a Cell-Penetrating MOTS-c Analogue Enhances Memory and Attenuates Aβ1–42- or LPS-Induced Memory Impairment through Inhibiting Neuroinflammation
Jinhong Jiang, Xin Chang, YaoYan Nie, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 9, pp. 1506-1518
Closed Access | Times Cited: 27
Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials
Irina Petrushina, Armine Hovakimyan, Indira S. Harahap-Carrillo, et al.
Neurobiology of Disease (2020) Vol. 139, pp. 104823-104823
Open Access | Times Cited: 31
What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials
Szofia Bullain, Rachelle S. Doody
Journal of Neurochemistry (2020) Vol. 155, Iss. 2, pp. 120-136
Open Access | Times Cited: 27
Novel presenilin 1 and 2 double knock-out cell line for in vitro validation of PSEN1 and PSEN2 mutations
Anna A. Pimenova, Alison Goate
Neurobiology of Disease (2020) Vol. 138, pp. 104785-104785
Open Access | Times Cited: 21
Plasma neurofilament light levels show elevation two years prior to diagnosis of amyotrophic lateral sclerosis in the UK Biobank
Erin N. Smith, Jonghun Lee, Daria Prilutsky, et al.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2023) Vol. 25, Iss. 1-2, pp. 170-176
Closed Access | Times Cited: 7
Targets, trials and tribulations in Alzheimer therapeutics
Ruchita Gharat, Gargi Dixit, Mihir Khambete, et al.
European Journal of Pharmacology (2023) Vol. 962, pp. 176230-176230
Closed Access | Times Cited: 7
Aggregation Mechanism of Alzheimer’s Amyloid β-Peptide Mediated by α-Strand/α-Sheet Structure
Anand Balupuri, Kwang-Eun Choi, Nam Sook Kang
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 3, pp. 1094-1094
Open Access | Times Cited: 16
Calabria as a Genetic Isolate: A Model for the Study of Neurodegenerative Diseases
Francesco Bruno, Valentina Laganà, Raffaele Di Lorenzo, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2288-2288
Open Access | Times Cited: 10
2018 Yearbook of Neurorestoratology
Hongyun Huang, Hari Shanker Sharma, Lin Chen, et al.
Journal of Neurorestoratology (2019) Vol. 7, Iss. 1, pp. 8-17
Open Access | Times Cited: 17
Transgenerational Interaction of Alzheimer’s Disease with Schizophrenia through Amyloid Evolvability
Yoshiki Takamatsu, Gilbert Ho, Masaaki Waragai, et al.
Journal of Alzheimer s Disease (2019) Vol. 68, Iss. 2, pp. 473-481
Open Access | Times Cited: 16
Intranasal MMI-0100 Attenuates Aβ1−42- and LPS-Induced Neuroinflammation and Memory Impairments via the MK2 Signaling Pathway
Jinhong Jiang, Zhe Wang, Xueya Liang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 14
GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects
Hyun‐Hee Park, Hyuk Sung Kwon, Kyu‐Yong Lee, et al.
Aging (2024)
Open Access | Times Cited: 1
Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice
Shuo Xiao, Linlin Song, Jiangtao Li, et al.
Journal of Alzheimer s Disease (2019) Vol. 73, Iss. 2, pp. 657-670
Closed Access | Times Cited: 9
Calabria as a Genetic Isolate, a Model for the Study of Neurodegenerative Diseases
Francesco Bruno, Valentina Laganà, Raffaele Di Lorenzo, et al.
(2022)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top